Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6570451 | 1.00 | L3MBTL1 (0.37) | L3MBTL1MAPK1ALDH1A1KMT2ALPAR1 | |
| SCHEMBL6570448 | 1.00 | L3MBTL1 (0.37) | L3MBTL1MAPK1ALDH1A1KMT2ALPAR1 | |
| Timcodar SCHEMBL1492143 | 1.00 | L3MBTL1 (0.37) | L3MBTL1MAPK1ALDH1A1KMT2ALPAR1 | |
| Timcodar SCHEMBL30929684 | 0.96 | ALDH1A1 (0.36) | L3MBTL1MAPK1ALDH1A1KMT2ALPAR1 | |
| SCHEMBL6573929 | 0.95 | L3MBTL1 (0.40) | L3MBTL1MAPK1ALDH1A1KMT2ALPAR1 | |
| SCHEMBL6573934 | 0.95 | L3MBTL1 (0.40) | L3MBTL1MAPK1ALDH1A1KMT2ALPAR1 | |
| SCHEMBL6572477 | 0.93 | SLC2A1 (0.39) | L3MBTL1KMT2ALMNASMN1; SMN2SLC2A1 | |
| SCHEMBL6570405 | 0.93 | SLC2A1 (0.39) | L3MBTL1KMT2ALMNASMN1; SMN2SLC2A1 | |
| SCHEMBL6572534 | 0.92 | SLC2A4 (0.39) | L3MBTL1MAPK1ALDH1A1KMT2ALPAR1 | |
| SCHEMBL6570385 | 0.92 | SLC2A4 (0.39) | L3MBTL1MAPK1ALDH1A1KMT2ALPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 469 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159611-A1 | SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS) | YALE UNIVERSITY | 2023-05-25 | — | — | US | claimed |
| CN-109071622-B | Peptides with anticancer activity | IDP研发制药有限公司（ES） | 2023-01-13 | — | — | CN | claimed |
| EP-0797567-B1 | NOVEL AMINO ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY | VERTEX PHARMA (US) | 2004-02-11 | — | — | EP | claimed |
| US-5840736-A | PEPTIDES FOR NERVE GROWTH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-11-24 | — | — | US | claimed |
| EP-0797567-A1 | NOVEL AMINO ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY | Vertex Pharmaceuticals Incorporated (US) | 1997-10-01 | — | — | EP | claimed |
| US-5543423-A | USED IN MULTI-DRUG RESISTANCE CANCER THERAPY | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996015101-A1 | NOVEL AMINO ACID DERIVATIVES WITH IMPROVED MULTI-DRUG RESISTANCE ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1996-05-23 | — | — | WO | claimed |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| CN-122081247-A | Oncolytic vaccinia virus and recombinant viruses and methods of use thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-26 | — | — | US | disclosed |
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| WO-2026107113-A1 | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF | CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| EP-0946190-B1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE OUTGROWTH | VERTEX PHARMA (US) | 2003-09-24 | — | — | EP | disclosed |
| US-6284778-B1 | NEUROTROPHIC AGENT | VERTEX PHARMACEUTICALS INCORPORATED | 2001-09-04 | — | — | US | disclosed |
| US-6172086-B1 | TREATING PARKINSON*S DISEASE, ALZHIEMER*S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, MULTIPLE SCLEROSIS AND OTHER NERVOUS SYSTEM DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED | 2001-01-09 | — | — | US | disclosed |
| EP-0946190-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS | Vertex Pharmaceuticals Incorporated (US) | 1999-10-06 | — | — | EP | disclosed |
| US-5840736-A | PEPTIDES FOR NERVE GROWTH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998020891-A1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH USING COMPOUNDS WITH AFFINITY FOR FKBP12 IN COMBINATION WITH NEUROTROPHIC FACTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-05-22 | — | — | WO | disclosed |
| US-5543423-A | USED IN MULTI-DRUG RESISTANCE CANCER THERAPY | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1996-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159611-A1 | SMALL MOLECULE ADAPTER REGULATED, TARGET SPECIFIC CHIMERIC ANTIGEN RECEPTOR BEARING T CELLS (SMART CARS) | CD47, CD4, CD2 | L3MBTL1 2145/4885MAPK1 2213/4885ALDH1A1 4142/4885 |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | CASP9, TP53, CASP2 | L3MBTL1 718/4885MAPK1 2930/4885ALDH1A1 4707/4885 |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | GRIN1, GRIN3A, GRIN2A | L3MBTL1 1881/4885MAPK1 748/4885ALDH1A1 2319/4885 |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NPY1R | L3MBTL1 857/4885MAPK1 541/4885ALDH1A1 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.